These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 26364385)

  • 1. [Denosumab finds its way into the updated DVO guidelines].
    Fessler B
    Med Monatsschr Pharm; 2015 Apr; 38(4):147-8. PubMed ID: 26364385
    [No Abstract]   [Full Text] [Related]  

  • 2. Denosumab: an antifracture therapy for postmenopausal women with osteoporosis.
    Jiang X; Schnatz PF
    Menopause; 2013 Feb; 20(2):117-9. PubMed ID: 23299707
    [No Abstract]   [Full Text] [Related]  

  • 3. Denosumab: recent update in postmenopausal osteoporosis.
    Silva I; Branco JC
    Acta Reumatol Port; 2012; 37(4):302-13. PubMed ID: 24126422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis.
    Sutton EE; Riche DM
    Ann Pharmacother; 2012; 46(7-8):1000-9. PubMed ID: 22837347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denosumab, osteoporosis, and prevention of fractures.
    Kiechl S; Willeit J; Schett G
    N Engl J Med; 2009 Nov; 361(22):2188-9; author reply 2190-1. PubMed ID: 19940304
    [No Abstract]   [Full Text] [Related]  

  • 6. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
    Bruhn C
    Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe hypocalcemia following denosumab injection in a hemodialysis patient.
    McCormick BB; Davis J; Burns KD
    Am J Kidney Dis; 2012 Oct; 60(4):626-8. PubMed ID: 22854051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The RANKL pathway and denosumab.
    Dore RK
    Rheum Dis Clin North Am; 2011 Aug; 37(3):433-52, vi-vii. PubMed ID: 22023901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab for the treatment of osteoporosis and cancer-related conditions.
    Lewiecki EM; Bilezikian JP
    Clin Pharmacol Ther; 2012 Jan; 91(1):123-33. PubMed ID: 22158568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab.
    Capozzi A; Lello S; Pontecorvi A
    Gynecol Endocrinol; 2014 Jun; 30(6):403-8. PubMed ID: 24592987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical use of denosumab for the management of low bone mineral density in postmenopausal women.
    Harris KB; Nealy KL; Jackson DJ; Thornton PL
    J Pharm Pract; 2012 Jun; 25(3):310-8. PubMed ID: 22550161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denosumab for the management of postmenopausal osteoporosis.
    Singer A; Grauer A
    Postgrad Med; 2010 Nov; 122(6):176-87. PubMed ID: 21084794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab update.
    Lewiecki EM
    Curr Opin Rheumatol; 2009 Jul; 21(4):369-73. PubMed ID: 19424068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study.
    Bolognese MA; Teglbjærg CS; Zanchetta JR; Lippuner K; McClung MR; Brandi ML; Høiseth A; Lakatos P; Moffett AH; Lorenc RS; Wang A; Libanati C
    J Clin Densitom; 2013; 16(2):147-53. PubMed ID: 22521543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Denosumab efficient against osteoporosis. A biological drug gives new possibilities to treat a public disease].
    Törring O
    Lakartidningen; 2010 Mar 3-9; 107(9):574-5. PubMed ID: 20387753
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of osteoporosis with Denosumab].
    Ferrari S
    Ther Umsch; 2012 Mar; 69(3):182-6. PubMed ID: 22403111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
    Josse R; Khan A; Ngui D; Shapiro M
    Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An autoimmune-mediated strategy for prophylactic breast cancer vaccination.
    Womens Health (Lond); 2010 Jul; 6(4):493. PubMed ID: 20597611
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.